Merck, Roche, BMS impress at ASCO, but questions linger
This article was originally published in Scrip
Executive Summary
Experimental cancer-fighting drugs from Roche, Bristol-Myers Squibb and Merck & Co. lived up to their advanced billings at a major medical meeting over the weekend, but the impressive data also raised questions about the next steps forward.